NCT03301168ACTIVE_NOT_RECRUITINGanonymous

Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders

Sponsor

Source record

Bellicum Pharmaceuticals

Phase

Source record

PHASE1

Modality

AI-normalized

cell therapy

Target

AI-normalized

BPX-501 T cells, Rimiducid

Indication / condition

AI-normalized

Acute Lymphoblastic Leukemia

Intervention

Source record

BPX-501 T cells, Rimiducid

Related intelligence directories

Indication directory: Acute Lymphoblastic Leukemia Modality directory: cell therapy Target directory: BPX-501 T cells

Source & freshness

Source record

NCT ID

NCT03301168

Original source

ClinicalTrials.gov

Source last updated

Jul 12, 2022

Ingested at

Jun 19, 2026

Internal sync

Jun 19, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT03301168

Title

Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders

Sponsor

Bellicum Pharmaceuticals

Status

ACTIVE_NOT_RECRUITING

Phase

PHASE1

Condition raw

Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Primary Immune Deficiency Disorder, Osteopetrosis, Cytopenia, Hemoglobinopathy in Children, Anemia, Aplastic

Condition normalized

Modality raw

cell therapy

Modality normalized

cell therapy

Target raw

BPX-501 T cells, Rimiducid

Target normalized

BPX-501 T cells, Rimiducid

Interventions

BPX-501 T cells, Rimiducid

Public preview

Source record

This study will evaluate pediatric patients with malignant or non-malignant blood cell disorders who are having a blood stem cell transplant depleted of T cell receptor (TCR) alfa and beta cells that comes from a partially matched family donor. The study will assess whether immune cells, called T cells, from the family donor, that are specially grown in the laboratory and given back to the patient along with the stem cell transplant can help the immune system recover faster after transplant. As a safety measure these T cells have been programmed with a self-destruct switch so that they can be destroyed if they start to react against tissues (graft versus host disease).

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 19, 2026

NCT ID

NCT03301168

Status

ACTIVE_NOT_RECRUITING

Phase

PHASE1

Sponsor

Bellicum Pharmaceuticals

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedJul 12, 2022

Internal syncJun 19, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03301168

Indication

Acute Lymphoblastic Leukemia

Modality

cell therapy

Target

BPX-501 T cells, Rimiducid

Intervention

BPX-501 T cells, Rimiducid

Source record